Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of advanced and neoadjuvant breast cancer, advanced non-small cell lung cancer, gastric and esophageal cancer, brain metastasis, solid tumors, and glioblastoma. It is also involved in the development of Utidelone capsule that is in Phase II/III clinical trials; Utidelone nanoformulation; and Utidelone antibody drug conjugate, as well as other active pharmaceutical ingredients, such as BG22, BG18, and BG44 in early development stages. The company develops its pharmaceutical products through its technology platforms, including combinatorial biosynthesis, microbial fermentation production, and microbial drug formulation development platforms.